|
|
|
|
Micro Imaging Tech to expand sales, manufacturing in Asia
Calfornian company, Micro Imaging Technology (MIT) has entered into a strategic business development relationship with OPH Hong Kong who will be instrumental in securing a manufacturing partner for the MIT in Asia.MIT has developed and...
|
|
|
Combination of Daptomycin plus Ceftriaxone Is More Active than Vancomycin plus Ceftriaxone in Experimental Men
Antimicrobial Agents and Chemotherapy, July 2009, p.3030-3033, Vol. 53, No. 7 Copyright 2009, American Society for Microbiology. All Rights Reserved. Egermann,1 Z. Stanga,1 A. Ramin,4 F. Acosta,1 A. Stucki,1 P. Gerber,2...
|
|
|
Advaxis Engages the Numoda Corporation to Oversee Phase II Clinical Trials of ADXS11-001
- Advaxis, Incorporated (OTCBB: ADXS), has engaged the Numoda Corporation, a leading clinical trial and logistics management company, to oversee Phase II clinical activity with ADXS11-001 for the treatment of invasive cervix cancer and...
|
|
|
Advaxis Engages the Numoda Corporation to Oversee Phase II Clinical Trials of ADXS11-001
- Advaxis, Incorporated (OTCBB: ADXS), has engaged the Numoda Corporation, a leading clinical trial and logistics management company, to oversee Phase II clinical activity with ADXS11-001 for the treatment of invasive cervix cancer and...
|
|
|
Advaxis Engages the Numoda Corporation to Oversee Phase II Clinical Trials of ADXS11-001
Advaxis, Incorporated (OTCBB: ADXS) Numoda will integrate oversight and logistical functions with the clinical research organizations (CRO), contract laboratories, academic laboratories and statistical groups involved.The Numoda...
|
|
|
Derma Sciences Announces First Commercial Sales of BIOGUARD(TM) Barrier Dressings
PRINCETON, N.J., June 23 /PRNewswire-FirstCall/ -- Derma Sciences, Inc., a provider of advanced wound care products, announced today that it has begun shipping BIOGUARD(TM) Barrier Dressings to customers. Separately, the company...
|
|
|
Food poisoning on the rise in elderly
Listeria poisonings are on the rise because the elderly are taking chances with use-by dates, newspapers reported.Brought to you by NHS Choices The Times said that the waste not, want not ethos of the post-war period could be...
|
|
|
Reengineering A Food Poisoning Microbe To Carry Medicines And Vaccines
Scientists have used genetic engineering to tame one of the most deadly food poisoning microbes and turn it into a potential new way of giving patients medicine and vaccines in pills rather than injections.The study is in the current...
|
|
|
Older People Taking More Risks With Food Safety
People over the age of 60 are more likely than younger people to take risks with 'use by' dates, according to new research findings published by the Food Standards Agency.Eating food beyond its 'use by' date increases the risk of food...
|
|
|
Reengineering A Food Poisoning Microbe To Carry Medicines And Vaccines
Scientists have used genetic engineering to tame one of the most deadly food poisoning microbes and turn it into a potential new way of giving patients medicine and vaccines in pills rather than injections.Colin Pouton and colleagues note...
|
|
|
AdvaxisEUR Clinical Trial Survival Data Significantly Exceeds the National Cancer Institute's Median Surviva
23% of Stage-Four Metastatic Cervix Cancer Patients Treated With Live Listeria Vaccine ADXS11-001 Alive After 3 Years NORTH BRUNSWICK, N.J.--(BUSINESS WIRE)--Advaxis, Incorporated (OTCBB: ADXS), has updated survival data for its Phase...
|
|
|
Advaxis Clinical Trial Survival Data Significantly Exceeds the National Cancer Institute's Median Survival
- Advaxis, Incorporated (OTCBB: ADXS), has updated survival data for its Phase I clinical trial (Trial) of its live Listeria vaccine ADXS11-001(formerly named Lovaxin-C) in the treatment of advanced, metastatic cervix patients who have...
|
|
|
Advaxis' Clinical Trial Survival Data Significantly Exceeds the National Cancer Institute's
BusinessWire - Advaxis, Incorporated (OTCBB: ADXS), has updated survival data for its Phase I clinical trial (Trial) of its live Listeria vaccine ADXS11-001(formerly named Lovaxin-C) in the treatment of advanced, metastatic cervix...
|
|
|
AdvaxisEUR Clinical Trial Survival Data Significantly Exceeds the National Cancer Institute's Median Surviva
Advaxis, Inc : orporated (OTCBB: ADXS), has updated survival data for its Phase I clinical trial (Trial) of its live Listeria vaccine ADXS11-001(formerly named Lovaxin-C) in the treatment of advanced, metastatic cervix patients who...
|
|
|
Advaxis' Clinical Trial Survival Data Significantly Exceeds the National Cancer Institute's Median Survival St
23% of Stage-Four Metastatic Cervix Cancer Patients Treated With Live Listeria Vaccine ADXS11-001 Alive After 3 Years NORTH BRUNSWICK, N.J.--(BUSINESS WIRE)--Advaxis, Incorporated (OTCBB: ADXS - News) As of June 12, 2009 three (3) of...
|
|
|
Advaxis' Clinical Trial Survival Data Significantly Exceeds the National Cancer Institute's Median Survival St
23% of Stage-Four Metastatic Cervix Cancer Patients Treated With Live Listeria Vaccine ADXS11-001 Alive After 3 Years NORTH BRUNSWICK, N.J.--(BUSINESS WIRE)--Advaxis, Incorporated (OTCBB: ADXS - News) As of June 12, 2009 three (3) of...
|
|
|
Advaxis' Clinical Trial Survival Data Significantly Exceeds the National Cancer Institute's Median Survival St
NORTH BRUNSWICK, N.J.--(BUSINESS WIRE)-- Advaxis, Incorporated (OTCBB: ADXS), has updated survival data for its Phase I clinical trial (Trial) of its live Listeria vaccine ADXS11-001(formerly named Lovaxin-C) in the treatment of...
|
|
|
Advaxis' Clinical Trial Survival Data Significantly Exceeds the National Cancer Institute's Median Survival St
NORTH BRUNSWICK, N.J.--(BUSINESS WIRE)-- Advaxis, Incorporated (OTCBB: ADXS), has updated survival data for its Phase I clinical trial (Trial) of its live Listeria vaccine ADXS11-001(formerly named Lovaxin-C) in the treatment of...
|
|
|
Advaxis' Clinical Trial Survival Data Significantly Exceeds the National Cancer Institute's Median Survival St
Advaxis, Incorporated ( OTCBB:ADXS), has updated survival data for its Phase I clinical trial (Trial) of its live Listeria vaccine ADXS11-001(formerly named Lovaxin-C) in the treatment of advanced, metastatic cervix patients who have...
|
|
|
AdvaxisEUR Clinical Trial Survival Data Significantly Exceeds the National Cancer Institute's Median Surviva
NORTH BRUNSWICK, N.J.--(BUSINESS WIRE)--Advaxis, Incorporated (OTCBB: ADXS), has updated survival data for its Phase I clinical trial (Trial) of its live Listeria vaccine ADXS11-001(formerly named Lovaxin-C) in the treatment of...
|
|
|
Advaxis' Clinical Trial Survival Data Significantly Exceeds the National Cancer Institute's Median Survival St
three (3) of the thirteen (13) evaluable patients in the Trial, approximately twenty-three percent (23%), are still alive at 981 days, 949 days and 850 days, respectively.The Trial's median patient survival was 347 days. Of the 15...
|
|
|
Advaxis Clinical Trial Survival Data Significantly Exceeds the National Cancer Institute's Median Survival
three (3) of the thirteen (13) evaluable patients in the Trial, approximately twenty-three percent (23%), are still alive at 981 days, 949 days and 850 days, respectively.The Trial's median patient survival was 347 days. Of the 15...
|
|
|
Advaxis' Clinical Trial Survival Data Significantly Exceeds the National Cancer Institute's Median Survival St
These figures significantly exceed the median survival rate established by the National Cancer Institute's Gynecologic Oncology Group (GOG).The GOG's median survival rate varies between 3.8 and 6.2 months in studies of patients who have...
|
|
|
MIT 1000 Rapid Microbial Identification System Receives AOAC Research Institute Listeria Performance Test Meth
Infectious Diseases / Bacteria / Viruses News Main Category: Infectious Diseases / Bacteria / Viruses email to a friend printer friendly view / write opinions rate article Current Article Ratings: Patient / Public: Health Professional:...
|
|
|
Micro Imaging Technology (MMTC) 1000 Rapid Microbial Identification System Receives AOAC Research Institute Li
- , Inc.(OTCBB: MMTC) announced that it has received (AOAC RI) Performance Test Method (PTM) certification for the MIT 1000 System's (System) identification of Listeria species (PTM Certificate Number 060901). Listeria are...
|
